Sign up to save your podcasts
Or
Share FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the recent advancements in the treatment of gastroesophageal junction (GEJ) and gastric cancer, focusing on the newly approved drug Zolbetuximab. They are joined by Dr. Kohei Shitara, the lead author of the pivotal SPOTLIGHT study, who shared insights on the mechanism of action of Zolbetuximab, its clinical trial findings, and the implications for patient care.
Key topics discussed include:
• The mechanism of action of Zolbetuximab and its target, Claudin 18.2.
• An overview of the GLOW and SPOTLIGHT studies, including study design and key findings on progression-free survival (PFS) and overall survival (OS).
• Practical considerations for administering Zolbetuximab in clinical practice, including dosing schedules and side effect management.
• The importance of testing for Claudin 18.2 and the challenges faced in rural settings without in-house testing.
• Future directions in the treatment landscape for gastric cancer, including potential combination therapies and emerging agents.
Join us for this informative discussion that highlights the changing standard of care in gastric cancer treatment and the exciting possibilities ahead for patients.
Don't forget to like, share, and subscribe for more insightful conversations in the world of oncology!
YouTube: https://youtu.be/BfpDHpqgHMs
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
View all episodes
By Oncology Brothers
4.8
3636 ratings
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the recent advancements in the treatment of gastroesophageal junction (GEJ) and gastric cancer, focusing on the newly approved drug Zolbetuximab. They are joined by Dr. Kohei Shitara, the lead author of the pivotal SPOTLIGHT study, who shared insights on the mechanism of action of Zolbetuximab, its clinical trial findings, and the implications for patient care.
Key topics discussed include:
• The mechanism of action of Zolbetuximab and its target, Claudin 18.2.
• An overview of the GLOW and SPOTLIGHT studies, including study design and key findings on progression-free survival (PFS) and overall survival (OS).
• Practical considerations for administering Zolbetuximab in clinical practice, including dosing schedules and side effect management.
• The importance of testing for Claudin 18.2 and the challenges faced in rural settings without in-house testing.
• Future directions in the treatment landscape for gastric cancer, including potential combination therapies and emerging agents.
Join us for this informative discussion that highlights the changing standard of care in gastric cancer treatment and the exciting possibilities ahead for patients.
Don't forget to like, share, and subscribe for more insightful conversations in the world of oncology!
YouTube: https://youtu.be/BfpDHpqgHMs
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Breast Cancer Update
62 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
109 Listeners
The NPR Politics Podcast
25,757 Listeners
ASCO Daily News
55 Listeners
The Curbsiders Internal Medicine Podcast
3,327 Listeners
Core IM | Internal Medicine Podcast
1,087 Listeners
OncoPharm
183 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
510 Listeners
Run the List
245 Listeners
Oncology Today with Dr Neil Love
55 Listeners
Two Onc Docs
166 Listeners
Blood Cancer Talks
49 Listeners